![](/fileadmin/_processed_/csm_LG_Draft_aece1073b5.jpg)
Locate Bio Ltd raises £9.2m venture capital
Locate Bio said it will use the fresh money to finance a clinical study of LDGraft, a bone graft substitute containing a sustained-release...
![](/fileadmin/_processed_/csm_Obstructive_Sleep_Apnea_Treatment_Genio_by_Nyxoah_083756dfdb.png)
Nyxoah signs a €37.5m loan with the European Investment Bank
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), located in Mont-Saint-Guibert, Belgium announced that it has signed a €37.5m loan facility agreement with...
![](/fileadmin/_processed_/csm_china_vs_usa_boxing-web_647d130897.jpg)
BIOSECURE Act could affect half of US biopharmaceutical development
In January 2024, the US Senate and House of Representatives introduced the BIOSECURE Act to prevent US companies that collaborate with "foreign...
![](/fileadmin/_processed_/csm_NOVo_New_434e85ba4f.png)
Obesity: reseachers switch on brown fat cells
The new discovery could herald a revolution in obesity research. If the principle discovered in male mice also applies in humans, therapeutics...
![](/fileadmin/_processed_/csm_Catalym_eb_68929d20e3.png)
Catalym raises US$150m
The aim in four Phase IIb trials starting in 2025 is to demonstrate the efficacy, safety and licensing potential of Visugromab plus Nivolumab in...
![](/fileadmin/_processed_/csm_NALFD_model_7770420204.png)
DefiniGEN and Atelerix prevent freezing damage in cell models
The agreement between the British companies combines DefiniGEN’s iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which...
![](/fileadmin/Content/NewsAndStories/2024/Enk_freitag.png)
Friday: CRISPR screen highlights genes behind T cell plasticity in autoimmunity
Pro-inflammatory CD4-positive T cells are major drivers of autoimmune diseases, yet therapiesmodulating T cell phenotypes to promote an...